SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.
Kevin N FranksLucy McParlandJoanne WebsterDavid R BaldwinDavid Sebag-MontefioreMatthew EvisonRichard BootonCorinne Faivre-FinnBabu NaiduJonathan FergusonClive PeedellMatthew E J CallisterMartyn KennedyJenny HewisonJanine BestallWalter M GregoryPeter HallFiona CollinsonCatherine OlivierRachel NaylorSue BellPeter AllenAndrew SlossMichael SneePublished in: The European respiratory journal (2020)
We conclude that a phase III RCT randomising higher risk patients between SABR and surgery is not feasible in the National Health Service. Patients have pre-existing treatment preferences, which was a barrier to recruitment. A significant proportion of patients randomised to the surgical group declined and chose SABR. SABR remains an alternative to surgery and novel study approaches are needed to define which patients benefit from a nonsurgical approach.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- minimally invasive
- prognostic factors
- randomized controlled trial
- clinical trial
- peritoneal dialysis
- stem cells
- phase iii
- open label
- small cell lung cancer
- mesenchymal stem cells
- coronary artery disease
- risk factors
- single cell
- study protocol
- quality improvement
- bone marrow
- atrial fibrillation
- percutaneous coronary intervention
- patient reported